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Abstract 
Background :Bisoprolol is an anti angina and ischemic therapy in patient with stable coronary 
artery disease (CAD). Moreover it can decrease mortality and rehospitalization rate up to 34 % 
and 28 %. However it is also known to increase erectile dysfunction risk. Leydig cells has beta 
receptor which contribute in testosterone release. The blockade of beta receptor by bisoprolol 
can inhibit testosterone release and cause erectile dysfunction (ED) 
Method :This retrospective case control study was done by age matched paired method. Men 
with CAD as diagnosed by angiography were evaluated for ED. Erectile function was assessed 
by a 5-item version of the International Index of Erectile Function (IIEF-5). History of disease 
and medical record were evaluated to check history of bisoprolol therapy for the last 6 month. 
Depression was screened using Indonesian version of Hospital Anxiety and Depression Scale 
(HADS). 
Result : From 157 total subject, patients were divided into 105 patients in case group and 52 
patients in control group. Ninety patients (85.7%) had history of bisoprolol therapy. The odd 
ratio of bisoprolol to have ED risk was 2, but there was not significant statistically (95% CI 0.85- 
2.93; p= 0.262). From sub analysis result 5 mg bisoprolol therapy have significant statistic result 
to ED risk (OR 2.65, 95% CI 1.12-6.25; p=0.026). Diabetes was another confounding factor 
which have significant risk to ED from multivariate analysis result (OR 3.8, 95 % CI 1.65-8.88, 
p=0.002). 
Conclussion : Stable CAD patients with bisoprolol therapy have a higher risk of ED compare 
with stable CAD patient without bisoprolol, however it was not statistically significant .
Keywords : Bisoprolol; erectile dysfunction; stable coronary artery disease
Introduction
Beta blocker are classified as one of 
coronary heart disease medical therapy. Beta 
blocker are indicated in myocardial infarction 
and chronic heart failure patients. Cardiac 
Insuficiency Bisoprolol Study II (CIBIS II) trial  
supported the use of betablocker in stable CAD 
patient.1  Bisoprolol used may decrease mortality 
and rehospitalization rate upto 34% and 28 
%. CIBIS II trial became evidence based for 
ESC guideline to include bisoprolol into one of 
coronary heart disease medical treatment.2
Bisoprolol was reported to cause erectile 
dysfunction as one of major complication. 
Bisoprolol may disrupt testosterone release from 
Leydig cell. Leydig cell have beta 1 receptors 
on its surface that have role on tertosterone 
secretion and metabolism. Leydig cell have 
approximately 25% beta 1 receptor and 75% 
beta-2 receptor. Disruption on testosterone 
release by beta blocker may cause decrease in 
serum testosterone level. Low serum testosterone 
level may impair sexual function. Bisoprolol are 
beta 1 selective blocker drugs which still have 
effect in sexual function. Therefore, side effect 
of bisoprolol therapy in sexual function at patient 
with CAD may cause erectile dysfunction.3
Our study aims to evaluate the risk of 
erectile dysfunction in patients with stable CAD 
treated with bisoprolol. 
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Methods 
This study was an observational study. 
The study design was case control retrospective 
which to asses risk of erectile dysfunction in 
stable CAD patient.This retrospective case 
control study was done by age paired matched 
method. Subject of this research were male 
with stable CAD who have been evaluated for 
bisoprolol used for last 6 month to asses ED 
risk. Men with stable CAD as diagnosed by 
angiography were evaluated for ED. Erectile 
function was assessed by a 5-item version of the 
International Index of Erectile Function (IIEF-5). 
History of disease and medical record were 
evaluated to check history of bisoprolol therapy 
for the last 6 month. 
The inclusion criteria for this research 
were patient that has been diagnosed stable 
CAD by angiography, active sexually for 
last 6 month, patient aged between 30 to 80 
years, patient who had Hospital Anxiety and 
Depresion Scale (HADS) < 8 and agreed to 
parcipitate in study. The exclusion criteria were 
patient with history of pelvic trauma, patient 
has been diagnosed with stroke, parkinsonism 
or encephalitic 
Every patient who had been diagnosed 
CAD by angiography was checked for history 
of  bisoprolol used in last 6 month at Cardiology 
Outpatient Clinic in Dr. Sardjito General Hospital 
. Another medical therapy for CAD such as 
angiotensin receptor blocker (ARB), calcium 
channel blocker (CCB) and diuretic were 
analyzed as confounding factor. 
Subject in this study were selected with 
age-paired match with less than 5 years in 
difference between age. Subjects has been 
taken with consecutive methods with proportion 
between case and control were 2:1. Patient that 
has been diagnosed as erectile dysfunction 
were included as case and patient that is not 
fulfill ED criteria were included as control. The 




Age in year, mean± SD 55.6±7.1 52.65±7.6 0.276
BMI, mean ± SD 24.94±3.4 24.41±3.2 0.553
CAD Medical Therapy, n (%)
Bisoprolol 90 (85.7) 39 (75) 0.262
Bisoprolol 1.25mg 10 (11.4) 9 (13.5) 0.450
Bisoprolol 2.5 mg 43 (41.9) 21(40.8) 0.400
Bisoprolol> 5 mg 37 (35.2) 9 (17.3) 0.015
Tiazide  10 (9.5) 3(5.8) 0.310
ACE Inhibitor 26 (24.9) 12 (23.1) 0.490
ARB 52 (49.5) 30 (57.7) 0.390
CCB 24 (22.9) 10 (19.2) 0.380
Traditional Risk Factor, n (%)
Diabetes mellitus 47 (44.8) 9 (17.4) 0.001
Hypertension  61 (58.1) 26 (50) 0.390
Dyslipidemia 66 (70.2) 28 (53.8) 0.300
Smoker  63(60.0) 28 (53.8) 0.490
Coronary Artery Disease, n (%)
CAD 1 VD 26(24.7) 18 (34.6) 0.265
CAD 2 VD 27 (25.7) 18 (34.6) 0.270
CAD 3 VD 52(49.5) 16(30.8) 0.019
ED is erectile dysfunction, SD is standard deviation, CAD is coronary artery disease, ACE is angiotensin 
converting enzyme, ARB is angiotensin receptor blocker, CCB is calcium channel blocker, VD is vessel 
disease 
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independent variable was bisoprolol used as 
CAD medical therapy and dependent variable 
of this study was ED. A statistical analysis was 
performed to analyse the relation between 
variables. An ethics committee of Faculty of 
Medicine Universitas Gadjah Mada – Dr. Sardjito 
Hospital had approved the study protocol.
Result 
The number of subject in this study was 
157 patients who divided into 105 patient in case 
group (ED) and 52 patient in control group (no 
ED). There was no significant difference between 
age in case group (55.6 ±7.071) or control group 
(52.65 ±7.6) with p value = 0.276. Total subjects 
who had bisoprolol therapy for last 6 month were 
90 patients from case group and 39 patients from 
control group. Bisoprolol therapy in this study 
were divided into several dose which were 1.25 
mg, 2.5mg and  > 5 mg. Most frequent bisoprolol 
used were in 2.5mg dose that is used by 43 case 
patient and 21 control patient. Another variable 
characteristic is shown in table 1 
The group who had bisoprolol therapy 
in this study, have ED risk with odd ratio value 
were 2 (95% CI 0.85-2.93, p=0.262). ED risk in 
bisoprolol therapy were shown in table 2. 
Factors in CAD patient who had ED as 
risk was shown in table 3 below. There were 2 
variables that had significant risk for ED in CAD 
patient. Those variable were diabetes (OR 3.87 
95% CI 1.7- 8.74) and CAD 3 VD ( OR 2.2 95% 
CI 1.09-4.45).  Another odd ratio value for each 
variable was shown in table 3 
 From multivariate analysis for risk factor of 
ED we have 2 significant variables. Those were 
bisoprolol therapy > 5 mg ( OR 2.65, 95% CI 1.12 
-6.26) and diabetes (OR 3.8  95% CI 1.65- 888) 
whose significantly increase risk of ED. Complete 
multivariate analysis result wasshown in table 4. 
Table 4. Multivariate analysis for ED risk in CAD 
patients
Variable Odd ratio 95% CI P value
Bisoprolol ≥ 5 mg 2.65 1.12– 6.26 0.026 
Diabetes 3.80 1.65 – 8.88 0.002 
CAD 3VD 2.01 0.96 – 4.20 0.063 
CAD is coronary artery disease, VD is vessel disease, 
CI is confidence interval
Discussion
A randomized controlled trial has been 
done to evaluate bisoprolol therapy response as 
an anti hypertension therapy. Erectile dysfunction 
(ED) has been analyzed as secondary outcome 
of bisoprolol therapy as an antihypertension. 
Table 2. Bivariate analysis of bisoprolol and ED risk
Group ED (n=105) no ED (n=52) Odd ratio 95% CI p value
Bisoprolol (+) 90 39 2 0.85-2.90 0.262
Table 3. Variables as risk  factor of ED




Bisoprolol 2 0.85 – 2.93 0.260 
Bisoprolol 5 mg 2.32 1.07 – 5.51 0.037* 
Thiazide 1.72 0.45 – 6.53 0.319 
CCB 1.24 0.54 – 2.80 0.380 
ACE 1.09 0.50 - 2.40    0.490 
ARB 0.71 0.37 – 1.41 0.390 
Traditional risk factor
Diabetes mellitus 3.87 1.70 – 8.74 0.001* 
Dyslipidemia 1.45 0.55 – 11.90 0.303 
Hypertension 1.38 0.71 – 2.70 0.395 
Smoking 1.28 0.65 – 2.51 0.495 
Coronary artery disease
1VD, n(%) 0.84 0.66 – 1.11 0.260 
2VD, n(%) 0.86 0.69 – 1.17 0.270 
3VD, n(%) 2.20 1.09 – 4.45 0.041* 
ACE is angiotensin converting enzyme, ARB is 
angiotensin receptor blocker, CCB is calcium channel 
blocker, VD is vessel disease, CI is confidence 
interval
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Cross sectional study about ED prevalence in 
hypertensive patient on beta blokertherapy has 
been reported. About 31-35% hypertensive patient 
with beta bloker therapy have sexual dysfunction as 
a secondary outcome. There was significant IIEF 
score difference between patient with bisoprolol 
and nebivolol therapy (21 vs 25; p<0.01).4 
A cohort study, which evaluated hypertensive 
therapy to erectile dysfunction risk, has been 
conducted in 2006. Two thousand five hundreds 
and ten hypertensive patients received medical 
therapy such as calcium channel blocker (CCB) 
(RR 1,6; 95% CI 1-2,4), diuretic (RR 1,3; 95 % 
CI 0,7-2,4) and Angiotensin ConvertingEnzyme 
inhibitor/ACE I (RR 0,9; 95 % CI 0,6-1,9). Beta 
blocker have highest relative risk (RR 1.97, 
95% CI 0.9-3.2).  These study shows that B 
blocker therapy may decrease sexual function 
in hypertensive patient.5  
Bisoprolol is B1 selective drugs, which 
can suppres Leydig cell activity to synthesis 
testosterone hormone. Furthermone, bisoprolol 
will decrease  total testosterone serum level. 
Disturbance in total testosterone serum level will 
increase risk of ED.7  The risk of ED in CAD patient 
has been assesed by IIEF score. Bisoprolol 
therapy in all dose did not give significant risk 
to ED in CAD patient (OR: 2.95 % CI 0.85-3.1; 
p= 0.26). However, in sub analysis there was 
significant ED risk for bisoprolol therapy > 5 mg 
(OR 2.65, 95% CI 1.12 – 6.26). 
Leydig cell has 25% B1 receptor on 
its surface which has function to stimulate 
testosterone release. B1 selective drugs will 
bind in these receptor and inhibit testosterone 
release. Decrease in total testosterone secretion 
will increase risk of ED. This study havesimilar 
result based on previous hypothesis about 
testosterone binding disturbance in leydig cell.3 
In 2002, Fogari et al found atenolol 
(another b1 selective drugs) was also decrease 
testosterone secretion that cause ED. Fogari 
found that atenolol therapy which given for 6 
month will increase ED risk in hypertensive patient. 
This study proves that atenolol as B1 selective 
drugs (similar with bisoprolol) also increase ED 
risk based on same pathophysiology.8 
Diabetes mellitus was one of confounding 
factor that significantly increase ED risk in this 
study with OR value was 3.8 (P = 002). Martin 
et al. also found in 2001 that diabetes was one 
of traditional risk factor that have significantly 
increase ED risk. Another confounding factor 
(CAD 3 VD, ARB, CCB, diuretic and smoking) 
did not have significant result  to increase ED 
risk in this study. 
Study limitation
In this study, testosterone serum level, 
which can affect risk of ED,was not measured. 
ED risk was measuredby IIEF quesioner. This 
study used case controlled age paired match 
method when randomized control trial will give 
better result but that method has ethical issue. 
Diabetes, which was most significant confounding 
factor of this study was not, excluded so there 
still bias possibility for result of this study.  
Conclusion
Coronary artery disease patients who 
had bisoprolol therapy for last 6 months have 
increase risk of erectile dysfunction but it was 
not statistically significant. Significant result was 
only found in patient who had bisoprolol therapy 
> 5 mg in dose.
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